{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:59:26Z","timestamp":1792645166021,"version":"4.5.0"},"reference-count":82,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psoriasis is a chronic and complex immune-mediated papulosquamous disease affecting almost 2% of the world population. The interaction between a genetically predisposed individual and environmental triggers leads to a vicious cycle involving autoreactive T cells, dendritic cells, keratinocytes and dermal cells. Up to 40% of the psoriasis cases develop disabling psoriatic arthritis and an equal number of patients also tend to develop metabolic syndrome as well as cardiovascular comorbidities; hence, this is no more considered to be a disease limited to skin only. Being a systemic disease, there is an urgent need to develop potential biomarkers for the assessment of disease severity, prediction of outcome of the therapeutic intervention and association with various systemic comorbidities. Diverse genetic markers not only function as predictors of diseases pathogenesis, but also help to predict development of psoriasis and psoriatic arthritis. Personalised medicine is customising the therapeutic needs of a psoriasis patient and improving the outcome as per the hints we receive from the various biomarkers. This review deals with the list of potential biomarkers proposed to be useful in psoriasis, though there is limited data validating their routine use in clinical practice and the progress so far made in the field of precision medicine for psoriasis.<\/jats:p>","DOI":"10.4103\/ijd.ijd_167_24","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T13:08:53Z","timestamp":1719925733000},"page":"256-263","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Biomarkers in Psoriasis: The Future of Personalised Treatment"],"prefix":"10.4103","volume":"69","author":[{"given":"Bikash R.","family":"Kar","sequence":"first","affiliation":[{"name":"From the Department of DVL, IMS and SUM Hospital, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharshini","family":"Sathishkumar","sequence":"additional","affiliation":[{"name":"Department of DVL, CMC, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Tahiliani","sequence":"additional","affiliation":[{"name":"Senior Consultatnt, P. D. Hinduja Hospital and Research Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchala","family":"Parthasarathi","sequence":"additional","affiliation":[{"name":"Director Anchala Skin Institute and Research Centre, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shekhar","family":"Neema","sequence":"additional","affiliation":[{"name":"Department of DVL, AFMC, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyaki","family":"Ganguly","sequence":"additional","affiliation":[{"name":"Department of DVL, AIIMS, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Venkatachalam","sequence":"additional","affiliation":[{"name":"Department of DVL, RIMS, Srikakulam, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrichand G.","family":"Parasramani","sequence":"additional","affiliation":[{"name":"Department of DVL, Leelavati Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haritha","family":"Komeravelli","sequence":"additional","affiliation":[{"name":"Consultant Dermatologist, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaykar","family":"Thomas","sequence":"additional","affiliation":[{"name":"Senior Consultant Dermatologist at Apollo Hospitals & KK Child Trust Hospital, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-4362.1996.tb03687.x","article-title":"Skin disease and socioeconomic conditions in rural Africa:Tanzania","volume":"35","author":"Gibbs","year":"1996","journal-title":"Int J Dermatol"},{"key":"R2-20240829","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/bjd.12230","article-title":"Is the prevalence of psoriasis increasing?A 30\u2013year follow-up of a population\u2013based cohort","volume":"168","author":"Danielsen","year":"2013","journal-title":"Br J Dermatol"},{"key":"R3-20240829","doi-asserted-by":"crossref","first-page":"adv00030","DOI":"10.2340\/00015555-3384","article-title":"Psoriasis and genetics","volume":"100","author":"Dand","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and systemic inflammatory diseases:Potential mechanistic links between skin disease and co-morbid conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J Invest Dermatol"},{"key":"R5-20240829","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints:Preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R6-20240829","first-page":"1443","article-title":"Biological biomarkers in psoriatic disease. A review","volume":"35","author":"de","year":"2008","journal-title":"J Rheumatol"},{"key":"R8-20240829","first-page":"463","article-title":"What are biomarkers?","volume":"2010","author":"Strimbu","journal-title":"Curr Opin HIV AIDS"},{"issue":"13","key":"R9-20240829","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/CCID.S227896","article-title":"Omics-driven biomarkers of psoriasis:Recent insights, current challenges, and future prospects","volume":"25","author":"Aydin","year":"2020","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R10-20240829","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/jcm8010115","article-title":"Familial aggregation of psoriasis and co-aggregation of autoimmune diseases in affected families","volume":"8","author":"Huang","year":"2019","journal-title":"J Clin Med"},{"key":"R11-20240829","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jdermsci.2020.05.008","article-title":"The current landscape of psoriasis genetics in 2020","volume":"99","author":"Ogawa","year":"2020","journal-title":"J Dermatol Sci"},{"key":"R12-20240829","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.0022-202X.2004.23511.x","article-title":"The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis","volume":"124","author":"Allen","year":"2005","journal-title":"J Invest Dermatol"},{"key":"R13-20240829","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000475809","article-title":"Serum human beta-defensin-2 is a possible biomarker for monitoring response to JAK inhibitor in psoriasis patients","volume":"233","author":"Jin","year":"2017","journal-title":"Dermatology"},{"key":"R14-20240829","doi-asserted-by":"crossref","first-page":"e64376","DOI":"10.1371\/journal.pone.0064376","article-title":"Single nucleotide polymorphisms in the tumor necrosis factor-alpha gene promoter region alter the risk of psoriasis vulgaris and psoriatic arthritis:A meta-analysis","volume":"8","author":"Zhu","year":"2013","journal-title":"PLoS One"},{"issue":"Suppl 2","key":"R15-20240829","first-page":"ii65","article-title":"Psoriasis assessment tools in clinical trials","volume":"64","author":"Feldman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R16-20240829","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","article-title":"Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment","volume":"51","author":"Langley","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R17-20240829","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1600-0625.2012.01518.x","article-title":"Etanercept restores a differentiated keratinocyte phenotype in psoriatic human skin:A morphological study","volume":"21","author":"Donetti","year":"2012","journal-title":"Exp Dermatol"},{"key":"R18-20240829","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000018422","article-title":"Changes in keratin 6 and keratin 10 (co-) expression in lesional and symptomless skin of spreading psoriasis","volume":"201","author":"Mommers","year":"2000","journal-title":"Dermatology"},{"key":"R19-20240829","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.0303-6987.2004.0220.x","article-title":"K16 expression in uninvolved psoriatic skin:A possible marker of pre-clinical psoriasis","volume":"31","author":"Bhawan","year":"2004","journal-title":"J Cutan Pathol"},{"key":"R20-20240829","doi-asserted-by":"crossref","first-page":"322","DOI":"10.4103\/2229-5178.164483","article-title":"Role of C-reactive protein as a marker of disease severity and cardiovascular risk in patients with psoriasis","volume":"6","author":"Vadakayil","year":"2015","journal-title":"Indian Dermatol Online J"},{"key":"R21-20240829","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3390\/cells10112991","article-title":"Human ?-defensin 2 and its postulated role in modulation of the immune response","volume":"10","author":"Cie\u015blik","year":"2021","journal-title":"Cells"},{"key":"R22-20240829","doi-asserted-by":"crossref","first-page":"e4725","DOI":"10.1371\/journal.pone.0004725","article-title":"Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin","volume":"4","author":"Jansen","year":"2009","journal-title":"PLoS One"},{"key":"R23-20240829","first-page":"5823684","article-title":"The pathophysiological mechanisms and the quest for biomarkers in psoriasis, a stress-related skin disease","volume":"2018","author":"Sarbu","year":"2018","journal-title":"Dis Markers"},{"key":"R24-20240829","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.3390\/jcm10153199","article-title":"Molecular pathogenesis of psoriasis and biomarkers reflecting disease activity","volume":"10","author":"Honma","year":"2021","journal-title":"J Clin Med"},{"key":"R25-20240829","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2133.2006.07198.x","article-title":"Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis","volume":"155","author":"Benoit","year":"2006","journal-title":"Br J Dermatol"},{"key":"R26-20240829","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.3390\/ijms21186791","article-title":"Psoriasis and antimicrobial peptides","volume":"21","author":"Takahashi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R27-20240829","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2022-222229","article-title":"Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease","volume":"81","author":"Mellor","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R28-20240829","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/exd.14151","article-title":"Vascular endothelial growth factor-A as a promising therapeutic target for the management of psoriasis","volume":"29","author":"Luengas-Martinez","year":"2020","journal-title":"Exp Dermatol"},{"key":"R29-20240829","doi-asserted-by":"crossref","first-page":"7361826","DOI":"10.1155\/2019\/7361826","article-title":"Association of serum lipocalin-2 concentrations with psoriasis and psoriatic arthritis:An updated meta-analysis","volume":"2019","author":"Wang","year":"2019","journal-title":"Dis Markers"},{"key":"R30-20240829","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.jid.2016.03.002","article-title":"Increased lipocalin-2 contributes to the pathogenesis of psoriasis by modulating neutrophil chemotaxis and cytokine secretion","volume":"136","author":"Shao","year":"2016","journal-title":"J Invest Dermatol"},{"key":"R31-20240829","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1080\/09546634.2021.1966357","article-title":"Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis","volume":"33","author":"Pourani","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"R32-20240829","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/00325481.2019.1643634","article-title":"Serum levels of YKL-40 are increased in patients with psoriasis:A meta-analysis","volume":"131","author":"Kong","year":"2019","journal-title":"Postgrad Med"},{"key":"R33-20240829","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.cyto.2014.12.014","article-title":"Cytokines in psoriasis","volume":"73","author":"Baliwag","year":"2015","journal-title":"Cytokine"},{"key":"R34-20240829","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00403-016-1620-4","article-title":"Association of toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis","volume":"308","author":"Smith","year":"2016","journal-title":"Arch Dermatol Res"},{"issue":"Suppl 2","key":"R35-20240829","doi-asserted-by":"crossref","first-page":"S1458","DOI":"10.4103\/jpbs.jpbs_251_21","article-title":"Reliability of C-reactive protein as a biomarker for cardiovascular and oral diseases in young and old subjects","volume":"13","author":"Barbi","year":"2021","journal-title":"J Pharm Bioallied Sci"},{"key":"R36-20240829","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1373\/clinchem.2014.232918","article-title":"GlycA:A Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation","volume":"61","author":"Otvos","year":"2015","journal-title":"Clin Chem"},{"key":"R37-20240829","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3389\/fimmu.2017.01908","article-title":"S100 proteins as an important regulator of macrophage inflammation","volume":"8","author":"Xia","year":"2018","journal-title":"Front Immunol"},{"key":"R38-20240829","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/bjd.14718","article-title":"Psoriasin (S100A7) promotes stress-induced angiogenesis","volume":"175","author":"Vegfors","year":"2016","journal-title":"Br J Dermatol"},{"key":"R39-20240829","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ced.13370","article-title":"Serum levels of psoriasin (S100A7) and koebnerisin (S100A15) as potential markers of atherosclerosis in patients with psoriasis","volume":"43","author":"Awad","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"R40-20240829","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.3389\/fimmu.2017.01976","article-title":"Adaptive natural killer cells integrate interleukin-18 during target-cell encounter","volume":"8","author":"Hammer","year":"2018","journal-title":"Front Immunol"},{"key":"R41-20240829","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/MI.2005.273","article-title":"Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity","volume":"2005","author":"Arican","year":"2005","journal-title":"Mediators Inflamm"},{"key":"R42-20240829","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3389\/fphar.2020.01238","article-title":"The inflammasome signaling proteins ASC and IL-18 as biomarkers of psoriasis","volume":"11","author":"Forouzandeh","year":"2020","journal-title":"Front Pharmacol"},{"key":"R43-20240829","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/jdv.12528","article-title":"Increased serum level of N-terminal Pro-B-type natriuretic peptide as a possible biomarker of cardiovascular risk in psoriatic patients","volume":"29","author":"Pietrzak","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R44-20240829","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2147\/OARRR.S206931","article-title":"Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis","volume":"11","author":"Peluso","year":"2019","journal-title":"Open Access Rheumatol"},{"key":"R45-20240829","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jaad.2018.08.003","article-title":"Angiotensin-converting enzyme and subclinical atherosclerosis in psoriasis:Is there any association?A case-control study","volume":"82","author":"Abdollahimajd","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R46-20240829","doi-asserted-by":"crossref","first-page":"7353420","DOI":"10.1155\/2019\/7353420","article-title":"Biomarkers of inflammation in obesitypsoriatic patients","volume":"2019","author":"Rodr\u0131guez-Cerdeira","year":"2019","journal-title":"Mediators Inflamm"},{"key":"R47-20240829","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/antiox11020282","article-title":"The involvement of oxidative stress in psoriasis:A systematic review","volume":"11","author":"Dobric\u0103","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"R48-20240829","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4062\/biomolther.2020.054","article-title":"The role of leptin in the association between obesity and psoriasis","volume":"29","author":"Hwang","year":"2021","journal-title":"Biomol Ther (Seoul)"},{"key":"R49-20240829","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12944-015-0039-9","article-title":"Increased serum resistin levels correlate with psoriasis:A meta-analysis","volume":"14","author":"Huang","year":"2015","journal-title":"Lipids Health Dis"},{"key":"R50-20240829","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jid.2019.07.727","article-title":"Interaction of resistin and systolic blood pressure in psoriasis severity","volume":"140","author":"Seth","year":"2020","journal-title":"J Invest Dermatol"},{"key":"R51-20240829","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1590\/abd1806-4841.20197716","article-title":"Psoriasis in obesity:Comparison of serum levels of leptin and adiponectin in obese subjects-cases and controls","volume":"94","author":"Bavoso","year":"2019","journal-title":"An Bras Dermatol"},{"key":"R52-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2017.02.018","article-title":"Psoriasis-like inflammation leads to renal dysfunction via upregulation of NADPH oxidases and inducible nitric oxide synthase","volume":"46","author":"Al-Harbi","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"R53-20240829","first-page":"1012","article-title":"Correlations between related-purine derivatives and renal disorders in patients with psoriasis vulgaris","volume":"17","author":"Nicolae","year":"2019","journal-title":"Exp Ther Med"},{"key":"R54-20240829","doi-asserted-by":"crossref","first-page":"108513","DOI":"10.1016\/j.clim.2020.108513","article-title":"Psoriatic arthritis under the influence of IFN?","volume":"218","author":"Dai","year":"2020","journal-title":"Clin Immunol"},{"key":"R55-20240829","doi-asserted-by":"crossref","first-page":"672515","DOI":"10.3389\/fphar.2021.672515","article-title":"From bed to bench and back:TNF-?, IL-23\/IL-17A, and JAK-dependent inflammation in the pathogenesis of psoriatic synovitis","volume":"12","author":"Silvagni","year":"2021","journal-title":"Front Pharmacol"},{"key":"R56-20240829","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/acr.23298","article-title":"Differentiating psoriatic arthritis from psoriasis without psoriatic arthritis using novel serum biomarkers","volume":"70","author":"Cretu","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R57-20240829","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/proteomes6010005","article-title":"Exploring the psoriatic arthritis proteome in search of novel biomarkers","volume":"6","author":"Mahendran","year":"2018","journal-title":"Proteomes"},{"key":"R58-20240829","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/exd.13378","article-title":"Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active psoriasis and localized with keratinocytes, dendritic cells and other leukocytes","volume":"26","author":"Fuentes-Duculan","year":"2017","journal-title":"Exp Dermatol"},{"key":"R59-20240829","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s40744-021-00365-1","article-title":"Differentiating psoriatic arthritis from osteoarthritis and rheumatoid arthritis:A narrative review and guide for advanced practice providers","volume":"8","author":"Saalfeld","year":"2021","journal-title":"Rheumatol Ther"},{"key":"R60-20240829","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1586\/1744666X.2016.1147954","article-title":"Biomarkers in psoriatic arthritis:A systematic literature review","volume":"12","author":"Generali","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"R61-20240829","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/1744666X.2020.1752667","article-title":"Pathway to biomarker discovery in psoriatic arthritis","volume":"16","author":"Chandran","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"R62-20240829","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3899\/jrheum.190602","article-title":"Serum microRNA sig- nature as a diagnostic and therapeutic marker in patients with psoriatic arthritis","volume":"47","author":"Wade","year":"2020","journal-title":"J Rheumatol"},{"key":"R63-20240829","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(19)31772-6","article-title":"Psoriasis biologics:A new era of choice","volume":"394","author":"Mahil","year":"2019","journal-title":"Lancet"},{"key":"R64-20240829","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1590\/abd1806-4841.20164655","article-title":"C-reactive protein serum level in patients with psoriasis before and after treatment with narrow-band ultraviolet B","volume":"91","author":"Farshchian","year":"2016","journal-title":"An Bras Dermatol"},{"key":"R65-20240829","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2133.2008.08628.x","article-title":"Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis","volume":"159","author":"Strober","year":"2008","journal-title":"Br J Dermatol"},{"key":"R66-20240829","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis:76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"R67-20240829","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jamadermatol.2019.0098","article-title":"Association of HLA-C*06:02 status with differential response to ustekinumab in patients with psoriasis:A systematic review and meta-analysis","volume":"155","author":"van","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R68-20240829","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1038\/s41467-021-25066-9","article-title":"Enhanced NF-?B signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis","volume":"12","author":"Andres-Ejarque","year":"2021","journal-title":"Nat Commun"},{"key":"R69-20240829","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1468-3083.2010.03947.x","article-title":"Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk:Results of a prospective longitudinal observational study","volume":"25","author":"Boehncke","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R70-20240829","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jaci.2009.08.046","article-title":"Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes","volume":"124","author":"Zaba","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"R71-20240829","first-page":"411","article-title":"The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis","volume":"3","author":"Jenneck","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"R72-20240829","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3390\/genes11101155","article-title":"Transcriptome profiling analyses in psoriasis:A dynamic contribution of keratinocytes to the pathogenesis","volume":"11","author":"Rioux","year":"2020","journal-title":"Genes (Basel)"},{"key":"R73-20240829","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/jdv.18292","article-title":"iTRAQ-based quantitative proteomics reveals biomarkers\/pathways in psoriasis that can predict the efficacy of methotrexate","volume":"36","author":"Yan","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R74-20240829","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/1346-8138.14308","article-title":"Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis:Possibility as a marker reflecting favorable response to anti-interleukin-17A agents","volume":"45","author":"Shibuya","year":"2018","journal-title":"J Dermatol"},{"key":"R75-20240829","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/1346-8138.15511","article-title":"Thymus and activation-regulated chemokine (TARC) in patients with psoriasis:Increased serum TARC levels in patients with generalized pustular psoriasis","volume":"47","author":"Kawasaki","year":"2020","journal-title":"J Dermatol"},{"key":"R76-20240829","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jid.2019.08.457","article-title":"High levels of platelet-lymphocyte complexes in patients with psoriasis are associated with a better response to anti- TNF-a therapy","volume":"140","author":"Sanz-Mart\u0131nez","year":"2020","journal-title":"J Invest Dermatol"},{"key":"R77-20240829","first-page":"e13457","article-title":"Neutrophil\/platelet to lymphocyte ratio in monitoring of response to TNF-a inhibitors in psoriatic patients","volume":"33","author":"Najar","year":"2020","journal-title":"Dermatol Ther"},{"key":"R78-20240829","doi-asserted-by":"crossref","first-page":"11567","DOI":"10.3748\/wjg.v21.i41.11567","article-title":"Non-invasive diagnosis of liver fibrosis and cirrhosis","volume":"21","author":"Lurie","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R79-20240829","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/bjd.15220","article-title":"Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis:A cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP)","volume":"176","author":"van","year":"2017","journal-title":"Br J Dermatol"},{"key":"R80-20240829","doi-asserted-by":"crossref","first-page":"e2123923","DOI":"10.1001\/jamanetworkopen.2021.23923","article-title":"Performance of the enhanced liver fibrosis test to estimate advanced fibrosis among patients with nonalcoholic fatty liver disease","volume":"4","author":"Younossi","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R81-20240829","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/jgh3.12430","article-title":"Hepascore predicts liver outcomes and all-cause mortality in long-term methotrexate users:A retrospective cohort study","volume":"4","author":"Wang","year":"2020","journal-title":"JGH Open"},{"key":"R82-20240829","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1468-3083.2012.04643.x","article-title":"Assessment of methotrexate hepatotoxicity in psoriasis patients:A prospective evaluation of four serum fibrosis markers","volume":"27","author":"Chl\u00e1dek","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R83-20240829","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamadermatol.2013.9336","article-title":"The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis","volume":"150","author":"Lynch","year":"2014","journal-title":"JAMA Dermatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_167_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:52:32Z","timestamp":1787838752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_167_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_167_24","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"2024-02-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}